Investigating neurodegenerative heterogeneity in cognitively unimpaired A4 pre‐randomization cohort

The heterogeneous nature of Alzheimer’s disease and uncertainty of determining disease severity and subtype can confound treatment effects in clinical trials. Computational methods for subtyping can assist in trial enrichment. This study investigates the latent heterogeneity and severity (including absence) of neurodegeneration in the cognitively unimpaired A4 cohort enriched for elevated amyloid.